CN107899064A - A kind of medicine-carried and the preparation method and its usage for having the liquid embolizing agent of developability concurrently - Google Patents
A kind of medicine-carried and the preparation method and its usage for having the liquid embolizing agent of developability concurrently Download PDFInfo
- Publication number
- CN107899064A CN107899064A CN201711029752.0A CN201711029752A CN107899064A CN 107899064 A CN107899064 A CN 107899064A CN 201711029752 A CN201711029752 A CN 201711029752A CN 107899064 A CN107899064 A CN 107899064A
- Authority
- CN
- China
- Prior art keywords
- embolizing agent
- liquid embolizing
- anion
- methyl
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a kind of preparation method and its usage for the medicine-carried liquid embolizing agent for having developability.The liquid embolizing agent is mixed in a certain ratio composition by anion-modified polyethylene polyvinyl copolymer (EVOH), solvent and developer.EVOH introduces anion group by the method for chemical modification or graft modification on macromolecular chain, these anion groups can be interacted by positive and negative charge and carry out absorption carriage to the chemotherapeutic anti-cancer agents of cationization.Solvent can be dimethyl sulfoxide (DMSO) (DMSO), N methyl pyrrolidones (NMP), ethanol or their mixture.Developer is micro-sized metal tantalum powder either contrast agent containing iodine, or their mixture.The liquid embolizing agent can be widely applied to intervention embolization, be particularly suitable for liver cancer Arterial chemotherapy and embolization treatment (TACE).
Description
Technical field
The invention belongs to TACE, post-transcatheter arterial chemoembolization (Trans Arterial Chemo Embolization) neck
Domain, and in particular to a kind of medicine-carried and the preparation method and its usage for having the liquid embolizing agent of developability concurrently.
Background technology
TACE, post-transcatheter arterial chemoembolization (Trans Arterial Chemo Embolization) is Japanese scholars
Yamada was proposed first in 1997.Be applied to the treatment of liver cancer earliest, have become now mid-term more than 90% and in
The mainstream iatrotechnics formula that the hepatocarcinoma patient in later stage can select.It refers under X-ray, passes through femoral artery, abdomen master using microtubular
Suppository targeting is filled into tumor focus position by artery, liver sustainer.Suppository carries out embolism resistance to supply artery of the tumor
It is disconnected, after tumor tissues blood supply is hindered so that tumour cannot grow necessary nutrition, achieve the purpose that tumour cell hungry to death.Remove
Outside this, if suppository has the function of to carry medicine, then, suppository can be released forming precisely targeting close to tumor focus annex
The effect of putting cancer therapy drug.Traditional systemic chemotherapy drug therapy is avoided for the unnecessary injury of human normal tissue.From
Liver cancer pathologic is analyzed, and hepatic tissue is by arteria hepatica and the dual blood supply of portal vein.The blood supply of normal liver tissue：75% is supplied by portal vein
Blood, 25% by arteria hepatica blood supply.The blood supply of normal liver tissue and the blood supply very different of hepatic carcinoma tissue.Hepatic carcinoma tissue
Blood supply 95%-99% come from arteria hepatica.Based on this species diversity, the liver of tumor locus is moved by arteria hepatica using microtubular
Arteries and veins carries out target administration, orients embolism.The drug concentration at tumor focus position can be so set to be higher by systemic chemotherapy 1 to 2
The order of magnitude, greatly protects normal liver tissue, realizes the purpose for killing tumour cell.Certainly, because liver tumour is mostly
Multiple blood supply, therefore Arterial chemotherapy and embolization treatment can only effectively kill tumor cells of hepatocellular carcinoma in a certain range certain area, it is difficult
To realize the purpose of radical cure liver cancer.But for the hepatocarcinoma patient of middle and later periods, tumour is usually both greater than 3cm or has been above
5cm, at this moment, if being capable of the development of effective symptom management, or even makes tumour progressively atrophy achievees the purpose that to extend patients ' lives,
Also can yet be regarded as a kind of valuable treatment means.
In TACE art formulas, lipiodol and microballoon are most commonly used that.For the demand of low-end market, lipiodol is as a kind of liquid
Suppository is cheap with its, and advantage easy to use becomes the first choice of doctor.And for the snowball of some high-end markets, carry
Medicine microballoon is then because the advantage of its medicine-carried becomes development trend in TACE art formulas.Lipiodol, this liquid suppository, it is maximum the shortcomings that
It is exactly that it cannot form permanent embolism, it can gradually be safely metabolised by the body at 1 month or so.So the blood vessel of embolism is able to again
It is logical.So often after transcatheter arterial embolization 1-2 months, patient needs embolism again.However, lipiodol is as liquid embolizing agent, it
Dispersivity, permeability, conduit passability are that microballoon or other embolism materials are incomparable.It can surpass choose it is very tiny
Vascularization embolism.And microballoon or other solid-state suppositories, it is minimum also just to block to 50 microns of blood vessels.Microballoon is as one
The new suppository of kind.Microballoon according to material used can be divided into polyvinyl alcohol microparticles, gelatine microsphere, sodium alginate micro ball,
Polylactic acid microsphere, o polyhydroxyethyl cellulose microballoon, polymethacrylate microballoon, chitosan microballoon, spherex.Microballoon
Usually there is excellent performance：Shape is regular, and size uniformity, surface is smooth, biological safety good compatibility, particle
Mutual bad adhesion, microballoon elastic deformability are good.And drug bearing microsphere has the chemical group of some negative electrical charges because of microsphere surface,
Therefore charge interaction can be leaned on to adsorb positively charged anticancer chemotherapeutic agent.Therefore, suspension of the microballoon in physiological saline
Stability and transporting in microtubular are all very good, and can pinpoint target slow-release chemotherapeutics to hepatic carcinoma tissue.
Drug bearing microsphere is more safe and effective as the therapeutic effect of suppository, is current most common suppository.According to the bolt in human body
The length of time is filled in, embolism microball can be divided into degradability microballoon and non-biodegradable microballoon.Wherein non-biodegradable microballoon bolt
Fill in after artery can permanence, there is powerful embolism to act on, play really permanent embolism effect.Foreign countries are existing more
Non-biodegradable embolism microball that is ripe and coming into operation, such as EmboSphere microballoons, HepaShpere microballoons, Bead
Block microballoons, DC Bead microballoons, LC Bead microballoons, SAP microballoons, Embozene microballoons, Tandem microballoons etc..This is slightly
Ball can embolism in the blood vessel for a long time, do not degraded by human body, therefore can always remain in patient body, form permanent embolism；And
And the development of most of microballoons now is individually carried out with administration, that is to say, that microballoon and contrast agent are being injected patient respectively
After in vivo, the separation of microballoon and contrast agent may be caused to disconnect, so that the specific location of microballoon cannot be observed exactly.Simply
Say, still also carry developing performance without a kind of microballoon so far.In addition, import microballoon is expensive, patient is difficult to bear.
The content of the invention
It is an object of the invention to overcome the shortcomings of above-mentioned technology, there is provided a kind of medicine-carried liquid embolizing agent and application thereof and
Preparation method.Onyx glue is a kind of new liquid suppository, allows to inject for a long time, has more preferable dispersivity and higher
Thrombosis rate, autography, and have the characteristics that non-adhering.Onyx glue is generally made in the embolism of cerebral arteriovenous malformation (AVM)
With.Onyx glue composition is very simple, it is by polyvinyl alcohol polyethylene and ethylene copolymers (EVOH), dimethyl sulfoxide (DMSO) (DMSO) solvent and micro-
Meter level tantalum powder forms.Therefore the present invention is optimized based on original Onyx glue.By the doing of EVOH polymer in Onyx glue
Learn modifying and decorating.By the chemical modification of the macromolecular chain to EVOH polymer, make macromolecular chain chemical bonding it is upper some it is cloudy from
Subbase group.These anionic groups can carry out absorption carriage to the cancer therapy drug of positively charged cationization.Retain at the same time
Former micro-sized metal tantalum powder makes the liquid embolizing agent have developability.And original DMSO solvents will be taken by 1-methyl-2-pyrrolidinone
Generation.The either mixed solvent of DMSO and 1-methyl-2-pyrrolidinone.By replacing solvent, it is possible to reduce the vascular toxicity of DMSO,
And it is for the Metabolic stress of liver function.Generally, the amount of suppository used in peripheral blood vessel embolism is intracranial vessel embolism
Twice it is even more.So DMSO is not suitable for the embolism of peripheral blood vessel.
5g EVOH polymers with 30mL 1-methyl-2-pyrrolidinones heating stirring dissolve, common sulfonating agent be the concentrated sulfuric acid,
Chlorosulfonic acid, sulfur trioxide, chlorosulfuric acid etc., can make catalyst with silver sulfate sometimes, accelerate the progress of reaction.Heating stirring reacts 2-
After 3 hours, room temperature cooling.Copolymer after cooling is poured into 200ml-300mL methanol, makes its Precipitation, takes precipitation to add
Enter 25mlN- methyl pyrrolidones to be allowed to be redissolved, add 200ml-300mL methanol and be allowed to separate out again, be so repeated several times,
Finally by drying precipitate.Or using vacuum drying.Sulfonation modifying EVOH copolymers, the N- crassitudes that will preferably obtain
Ketone, the mixing of Ta powder developer solutions certain proportion, stirring and dissolving, obtains liquid embolizing agent of the present invention.The load liquid body
Suppository will be provided with following characteristics：
1. product of the present invention as a kind of non-adhesive liquid embolic material there is autography to easily determine embolism starting point
And terminal, make embolism position more accurate.Easily by conveying microtubular, and compatible various commercially available microtubulars；
2. fluid present invention suppository main polymer has sulfonate group, therefore its cancer therapy drug with cationization
Ionic interaction, is eventually exhibited as the load to cationic drug and the effect of sustained release；
3. product viscosity of the present invention is low, good biocompatibility, no cytotoxicity, controllability are good.Will not causing after embolism
Or immunization, using safety；
4. 1-methyl-2-pyrrolidinone is safe as product solvent of the present invention, extra vascular destruction etc. will not be caused bad
Reaction；
5. product embolism permeability of the present invention, dispersivity are good, embolization effect is reliable and stable.
Zoopery proves that product of the present invention is suitable for the embolotherapy of good pernicious substantial viscera tumour and bleeding lesion.
Product of the present invention can be directly injected into aneurysm knurl intracavitary, adapt to the aneurysm cavity of different shape and size completely, make knurl wall and bolt
Any gap is not stayed between plug material, so as to achieve the purpose that permanent embolism.EVOH copolymers in the present invention, wherein polyethylene
It is 70%-30%, preferably 60-40% that alcohol, which accounts for shared molar ratio in copolymer,.The present invention is for EVOH copolymer polyethylene alcohol
The molar ratio that part carries out anion chemical modification is classified as 40%-10%, preferably 30%-20%.Liquid embolic of the present invention
Agent, is under normal conditions liquid, is solid after blood of human body is contacted.It can be applied to treat various vascular tumors.
Embodiment
Embodiment of the specific embodiment mode below in conjunction with specific embodiment
The above of the present invention is described in further detail
Embodiment 1
5g EVOH polymers 30mL 1-methyl-2-pyrrolidinones heating stirring dissolves, and sulfonating agent is concentrated sulfuric acid 5g,
Add a little about 0.01g silver sulfates to make catalyst, accelerate the progress of reaction.After 70 degree of heating stirrings react 3 hours, room temperature is cold
But.Copolymer after cooling is poured into 200ml-300mL methanol, makes its Precipitation, takes precipitation to add 25mlN- methylpyrroles
Alkanone is allowed to be redissolved, and adds 200ml-300mL methanol and is allowed to separate out again, is so repeated several times, finally by drying precipitate.
Or using vacuum drying.By the sulfonation modifying EVOH copolymers preferably obtained, 1-methyl-2-pyrrolidinone, Ta powder developer solutions
Certain proportion mixes, and stirring and dissolving, obtains liquid embolizing agent HW01 of the present invention.
Embodiment 2
5g EVOH polymers 30mL 1-methyl-2-pyrrolidinones heating stirring dissolves, and sulfonating agent is the concentrated sulfuric acid
2.5g, adds a little about 0.01g silver sulfates to make catalyst, accelerates the progress of reaction.After 70 degree of heating stirrings react 3 hours, room
Temperature cooling.Copolymer after cooling is poured into 200ml-300mL methanol, makes its Precipitation, takes precipitation to add 25mlN- methyl
Pyrrolidones is allowed to be redissolved, and adds 200ml-300mL methanol and is allowed to separate out again, is so repeated several times, finally by sediment
It is dry.Or using vacuum drying.By the sulfonation modifying EVOH copolymers preferably obtained, 1-methyl-2-pyrrolidinone, the development of Ta powder
Agent solution certain proportion mixes, and stirring and dissolving, obtains liquid embolizing agent HW02 of the present invention.(amount of sulfonation halves compared with HW01)
Embodiment 3
5g EVOH polymers 30mL 1-methyl-2-pyrrolidinones heating stirring dissolves, and sulfonating agent is chlorosulfonic acid 5g,
Add a little about 0.01g silver sulfates to make catalyst, accelerate the progress of reaction.After 70 degree of heating stirrings react 2 hours, room temperature is cold
But.Copolymer after cooling is poured into 200ml-300mL methanol, makes its Precipitation, takes precipitation to add 25mlN- methylpyrroles
Alkanone is allowed to be redissolved, and adds 200ml-300mL methanol and is allowed to separate out again, is so repeated several times, finally by drying precipitate.
Or using vacuum drying.By the sulfonation modifying EVOH copolymers preferably obtained, 1-methyl-2-pyrrolidinone, Ta powder developer solutions
Certain proportion mixes, and stirring and dissolving, obtains liquid embolizing agent HW03 of the present invention.
Embodiment 4
5g EVOH polymers 30mL 1-methyl-2-pyrrolidinones heating stirring dissolves, and sulfonating agent is chlorosulfonic acid
2.5g, adds a little about 0.01g silver sulfates to make catalyst, accelerates the progress of reaction.After 70 degree of heating stirrings react 2 hours, room
Temperature cooling.Copolymer after cooling is poured into 200ml-300mL methanol, makes its Precipitation, takes precipitation to add 25mlN- methyl
Pyrrolidones is allowed to be redissolved, and adds 200ml-300mL methanol and is allowed to separate out again, is so repeated several times, finally by sediment
It is dry.Or using vacuum drying.By the sulfonation modifying EVOH copolymers preferably obtained, 1-methyl-2-pyrrolidinone, the development of Ta powder
Agent solution certain proportion mixes, and stirring and dissolving, obtains liquid embolizing agent HW04 of the present invention.
Embodiment 5
5g EVOH polymers 30mL 1-methyl-2-pyrrolidinones heating stirring dissolves, and is acidulant with polyphosphoric acids 5g,
A little about 0.1g urea is added to accelerate the progress of reaction as catalyst.After 70 degree of heating stirrings react 6 hours, room temperature cooling.
Copolymer after cooling is poured into 200ml-300mL methanol, makes its Precipitation, takes precipitation to add 25mlN- methyl pyrrolidones
It is allowed to be redissolved, adds 200ml-300mL methanol and be allowed to separate out again, be so repeated several times, finally by drying precipitate.Or
Using vacuum drying.The phosphorylation preferably obtained is modified EVOH copolymers, 1-methyl-2-pyrrolidinone, Ta powder developer solution one
Certainty ratio mixes, and stirring and dissolving, obtains liquid embolizing agent HW05 of the present invention.
Embodiment 6
5g EVOH polymers 30mL 1-methyl-2-pyrrolidinones heating stirring dissolves, and is acidulant with concentrated nitric acid 5g, adds
A little about 0.01g silver nitrates accelerate the progress of reaction as catalyst.After 70 degree of heating stirrings react 4 hours, room temperature is cold
But.Copolymer after cooling is poured into 200ml-300mL methanol, makes its Precipitation, takes precipitation to add 25mlN- methylpyrroles
Alkanone is allowed to be redissolved, and adds 200ml-300mL methanol and is allowed to separate out again, is so repeated several times, finally by drying precipitate.
Or using vacuum drying.It is molten that the phosphorylation preferably obtained is modified EVOH copolymers, 1-methyl-2-pyrrolidinone, Ta powder developers
Liquid certain proportion mixes, and stirring and dissolving, obtains liquid embolizing agent HW06 of the present invention.
Derived above 6 are selected to be formulated and make contrast embolism with original Onyx and test：
The preoperative adriamycin with 150mg cationizations is formulated above to be sufficiently mixed.
The New Zealand rabbits 8, weight 2.5-3.5kg of liver cancer inductionization are selected, male and female are unlimited.Preoperative 1 fasting, it is preoperative
30min intramuscular injection atropine l mg, using ketalar combination Midazolam by domestic pig general anesthesia to satisfactory state.Isolate afterwards
Thigh arteria saphena is cut, and inserts 5F catheter sheaths, is intubated using 5F angiography catheter rows arteria carotis communis, injection of contrast agent row arteria carotis communis
Radiography.Afterwards microtubular is surpassed to select and recommend through guiding catheter under roadmap guides and be placed on liver into arteria hepatica, microtubular head end and move
The distal end of arteries and veins, does microtubular radiography.Product of the present invention is injected under fluoroscopic monitoring through microtubular 1-2ml syringes.By predetermined
Packet time follow-up observation, the follow-up observation time be respectively after embolism at once, 1 week, 4 weeks, 8 weeks, 12 weeks, M weeks, in follow-up observation
Hold for animal survival situation (diet, nervous system), check radiography, observation whether there is revascularization phenomenon；Animal is finally put to death, it is complete
Whole taking-up liver carries out histology pathological examination, in observation liver vessel and surrounding change, histology pathological examination.
Successful embolism has been carried out to 8 rabbits in experiment, technical difficulty, embolic processes are not run into during embolism and follow-up observation
Plugging phenomenon does not occur, tube drawing is smooth.And reconfirm copolymer to different type microtubular good compatibility.After embolism with
Visit observation experiment animal to survive well, diet and nerve, moving situation also occur without exception without deformity.Animal is put to death
After dissect, those suppository liver cancerous issues for employing anion-modified medicine-carried have different degrees of diminution.Using
The rabbit of Onyx embolisms and the rabbit of use HW series embolisms show obvious difference.Illustrate, the chemical modification of anion
Really the load for medicine and release play very positive effect.Clinical trial proves product of the present invention for good evil
Property carcinoma intervention embolism is curative for effect, safe and reliable.
The above is only some embodiments of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (10)
1. a kind of liquid embolizing agent, by the undissolved polymer of water, its solvent and micronized noble metal powder three into
Be grouped into, its embolism host agent is the undissolved polymer of water, the polymer features contain in the liquid embolizing agent polyethylene-
The copolymer of polyvinyl alcohol repetitive unit, and the chemical modification that anionic need to be done to polyvinyl alcohol repetitive unit is modified.
2. liquid embolizing agent according to claim 1, it is characterised in that polyvinyl alcohol repetitive unit is shared in the copolymer
Ratio is that molar ratio is 70%-30%, preferably 60-40%.
3. liquid embolizing agent according to claim 1, it is characterised in that carried out to polyvinyl alcohol part in EVOH copolymers
The molar ratio of anion chemical modification is classified as 40%-10%, preferably 30%-20%.
4. liquid embolizing agent according to claim 1, it is characterised in that copolymer is in 1-methyl-2-pyrrolidinone solvent
Liquid, is changed into solid in human vas is entered.
5. the liquid embolizing agent described in claim 1 is treating the application of various tumours, such as liver cancer, lung cancer.
6. liquid embolizing agent according to claim 1, wherein solvent can be 1-methyl-2-pyrrolidinones, or N- methyl
The mixed solvent of pyrrolidones and DMSO, or the mixed solvent of 1-methyl-2-pyrrolidinone, DMSO and absolute ethyl alcohol, either
The mixed solvent of 1-methyl-2-pyrrolidinone and absolute ethyl alcohol.
7. liquid embolizing agent according to claim 1, wherein developer can be micronized ta powders, or micro-
The platinum powder of riceization, or micronized platinum-tungsten alloys powder.
8. anion chemical modification according to claim 3, can carry out sulphur to polyvinyl alcohol part in EVOH copolymers
Change and be modified, phosphate anion is modified, and nitrate ion is modified, and purpose is to allow anion base on EVOH polymer chemical graft
Group.
9. the polymer of anion chemical modification according to claim 8, can form with the cancer therapy drug of cationization
Ionic interaction, improves its load and slow release effect for the cancer therapy drug of cationization, the anticarcinogen of cationization can
To be adriamycin, Irinotecan etc..
10. liquid embolizing agent according to claim 1, it is characterised in that carried out to polyvinyl alcohol part in EVOH copolymers
The molar ratio of anion chemical modification is classified as 40%-10%, preferably 30%-20%, can be by doing chemistry to EVOH copolymers
Modification obtains, but is not limited to by being chemically modified to obtain, and can also be realized by using the mode of functionalization monomer copolymerization.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711029752.0A CN107899064A (en) | 2017-10-27 | 2017-10-27 | A kind of medicine-carried and the preparation method and its usage for having the liquid embolizing agent of developability concurrently |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711029752.0A CN107899064A (en) | 2017-10-27 | 2017-10-27 | A kind of medicine-carried and the preparation method and its usage for having the liquid embolizing agent of developability concurrently |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107899064A true CN107899064A (en) | 2018-04-13 |
Family
ID=61842868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711029752.0A Pending CN107899064A (en) | 2017-10-27 | 2017-10-27 | A kind of medicine-carried and the preparation method and its usage for having the liquid embolizing agent of developability concurrently |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107899064A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111557898A (en) * | 2020-06-22 | 2020-08-21 | 珠海神平医疗有限公司 | Embolism agent and preparation method thereof |
| CN113398320A (en) * | 2021-02-04 | 2021-09-17 | 艾柯医疗器械(北京)有限公司 | Suspended particle contrast liquid embolic agent and preparation method thereof |
| CN113425886A (en) * | 2021-06-30 | 2021-09-24 | 上海交通大学医学院附属第九人民医院 | Vascular embolization agent and preparation method and application thereof |
| CN115068665A (en) * | 2022-02-09 | 2022-09-20 | 上海市第十人民医院 | Liquid embolic agent |
| CN115463246A (en) * | 2022-08-24 | 2022-12-13 | 中山大学附属第五医院 | Vascular embolization agent and preparation method and application thereof |
| WO2023125042A1 (en) * | 2021-12-31 | 2023-07-06 | 神泓医疗科技(上海)有限公司 | Liquid embolic agent, and preparation method therefor and use thereof |
| WO2023125036A1 (en) * | 2021-12-31 | 2023-07-06 | 神泓医疗科技(上海)有限公司 | Liquid embolism composition and use thereof, medical interventional instrument, and interventional therapy drug |
| WO2023125039A1 (en) * | 2021-12-31 | 2023-07-06 | 神泓医疗科技(上海)有限公司 | Liquid embolic agent and preparation method therefor and use thereof |
| WO2023174089A1 (en) * | 2022-03-14 | 2023-09-21 | 神泓医疗科技(上海)有限公司 | Liquid embolic agent, preparation method therefor, and application thereof |
| CN117582535A (en) * | 2024-01-18 | 2024-02-23 | 上海汇禾医疗科技股份有限公司 | Liquid embolic agent and preparation method thereof |
| CN117582535B (en) * | 2024-01-18 | 2024-04-26 | 上海汇禾医疗科技股份有限公司 | Liquid embolic agent and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005092406A1 (en) * | 2004-03-22 | 2005-10-06 | Advanced Cardiovascular Systems, Inc. | Phosphoryl choline coating compositions |
| CN101111273A (en) * | 2004-11-26 | 2008-01-23 | 斯坦托米克斯公司 | Chelating and binding chemicals to a medical implant, medical device formed, and therapeutic applications |
| CN101670095A (en) * | 2009-04-13 | 2010-03-17 | 北京大学 | Pharmaceutical composition for treating embolism and preparation method thereof |
| CN101716349A (en) * | 2009-12-16 | 2010-06-02 | 北京大学 | Medicine composite used for embolotherapy and acesodyne and preparation method thereof |
| CN102781974A (en) * | 2010-03-10 | 2012-11-14 | 克劳德伯纳德里昂第一大学 | Radiopaque, non- biodegradable, water - insoluble iodinated benzyl ethers of poly (vinyl alcohol), preparation method thereof, injectable embolizing compositions containing thereof and use thereof |
| CN106063946A (en) * | 2015-04-23 | 2016-11-02 | 柯惠Lp公司 | Absorbability oxidized cellulose thromboembolism forms solution |
-
2017
- 2017-10-27 CN CN201711029752.0A patent/CN107899064A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005092406A1 (en) * | 2004-03-22 | 2005-10-06 | Advanced Cardiovascular Systems, Inc. | Phosphoryl choline coating compositions |
| CN101111273A (en) * | 2004-11-26 | 2008-01-23 | 斯坦托米克斯公司 | Chelating and binding chemicals to a medical implant, medical device formed, and therapeutic applications |
| CN101670095A (en) * | 2009-04-13 | 2010-03-17 | 北京大学 | Pharmaceutical composition for treating embolism and preparation method thereof |
| CN101716349A (en) * | 2009-12-16 | 2010-06-02 | 北京大学 | Medicine composite used for embolotherapy and acesodyne and preparation method thereof |
| CN102781974A (en) * | 2010-03-10 | 2012-11-14 | 克劳德伯纳德里昂第一大学 | Radiopaque, non- biodegradable, water - insoluble iodinated benzyl ethers of poly (vinyl alcohol), preparation method thereof, injectable embolizing compositions containing thereof and use thereof |
| CN106063946A (en) * | 2015-04-23 | 2016-11-02 | 柯惠Lp公司 | Absorbability oxidized cellulose thromboembolism forms solution |
Non-Patent Citations (1)
| Title |
|---|
| 林泽昊: "乙烯-乙烯醇共聚物的官能化改性及其膜材料性能研究", 《中国优秀硕士学位论文全文数据库工程科技Ι辑》 * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111557898B (en) * | 2020-06-22 | 2023-02-28 | 珠海神平医疗有限公司 | Embolism agent and preparation method thereof |
| CN111557898A (en) * | 2020-06-22 | 2020-08-21 | 珠海神平医疗有限公司 | Embolism agent and preparation method thereof |
| CN113398320A (en) * | 2021-02-04 | 2021-09-17 | 艾柯医疗器械(北京)有限公司 | Suspended particle contrast liquid embolic agent and preparation method thereof |
| CN113398320B (en) * | 2021-02-04 | 2022-05-13 | 艾柯医疗器械(北京)有限公司 | Suspended particle contrast liquid embolic agent and preparation method thereof |
| WO2022166568A1 (en) * | 2021-02-04 | 2022-08-11 | 艾柯医疗器械(北京)有限公司 | Suspended particle contrast liquid embolic agent and preparation method therefor |
| CN113425886A (en) * | 2021-06-30 | 2021-09-24 | 上海交通大学医学院附属第九人民医院 | Vascular embolization agent and preparation method and application thereof |
| WO2023125036A1 (en) * | 2021-12-31 | 2023-07-06 | 神泓医疗科技(上海)有限公司 | Liquid embolism composition and use thereof, medical interventional instrument, and interventional therapy drug |
| WO2023125042A1 (en) * | 2021-12-31 | 2023-07-06 | 神泓医疗科技(上海)有限公司 | Liquid embolic agent, and preparation method therefor and use thereof |
| WO2023125039A1 (en) * | 2021-12-31 | 2023-07-06 | 神泓医疗科技(上海)有限公司 | Liquid embolic agent and preparation method therefor and use thereof |
| CN115068665A (en) * | 2022-02-09 | 2022-09-20 | 上海市第十人民医院 | Liquid embolic agent |
| WO2023174089A1 (en) * | 2022-03-14 | 2023-09-21 | 神泓医疗科技(上海)有限公司 | Liquid embolic agent, preparation method therefor, and application thereof |
| CN115463246A (en) * | 2022-08-24 | 2022-12-13 | 中山大学附属第五医院 | Vascular embolization agent and preparation method and application thereof |
| CN117582535A (en) * | 2024-01-18 | 2024-02-23 | 上海汇禾医疗科技股份有限公司 | Liquid embolic agent and preparation method thereof |
| CN117582535B (en) * | 2024-01-18 | 2024-04-26 | 上海汇禾医疗科技股份有限公司 | Liquid embolic agent and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107899064A (en) | A kind of medicine-carried and the preparation method and its usage for having the liquid embolizing agent of developability concurrently | |
| US11911041B2 (en) | Embolic compositions | |
| EP3607981A1 (en) | Kit for treating or relieving pain at incision site following surgical procedure | |
| AU2007356895B2 (en) | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same | |
| BR112014031223B1 (en) | POLYMER TREATMENT COMPOSITIONS | |
| JP2003502131A (en) | Method for embolizing a vascular site using an embolizing composition | |
| KR20130051916A (en) | Radiopaque, non-biodegradable, water-insoluble iodinated benzyl ethers of poly [vinyl alcohol], preparation method thereof, injectable embolizing compositions containing thereof and use thereof | |
| JP2000502321A (en) | Novel compositions for vascular embolization | |
| US11291748B2 (en) | Embolism material for blood vessel, preparation method therefor and use thereof in preparation of drugs | |
| CN105462142B (en) | A kind of temperature sensitive type interpenetration network hydrogel material and its preparation method and application | |
| US20200093745A1 (en) | Biodegradable drug eluting microsphere for the treatment of solid tumors | |
| Regine et al. | Embolization of traumatic and non-traumatic peripheral vascular lesions with Onyx | |
| Ko et al. | Recent progress in liquid embolic agents | |
| US20230277719A1 (en) | Liquid Embolic Compositions with Controlled Release of Radiopaque and Therapeutic Compounds and Methods of Using the Same | |
| CN111557898B (en) | Embolism agent and preparation method thereof | |
| WO2020221283A1 (en) | Ethanol hardener and use thereof | |
| CN107875436A (en) | A kind of composition of liquid embolizing agent for loading sodium bicarbonate powder and application thereof | |
| CN103751856B (en) | A kind of polylactic acid embolism microsphere with good dispersion | |
| EP3880724A1 (en) | Polymer for liquid embolic agents and method of obtaining same | |
| CN115845117B (en) | Embolic agent | |
| CN110527007A (en) | Poly- (2- alpha-cyanoacrylate) and its preparation method and application | |
| CN114177344B (en) | Liquid embolic agent and preparation method and application thereof | |
| CN116115819B (en) | Developable in-situ crosslinking embolic composition and method of use thereof | |
| WO2014116043A1 (en) | Biodegradable microbeads comprising dextran methacrylate and biocompatible anionic polymer, and preparation method therefor | |
| CN114984296A (en) | Thermally induced hydrogel embolic agent with X-ray developing capability and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20191220 Address after: 310012 room 380, building 3, No. 16, Zhuantang science and technology economic block, Xihu District, Hangzhou City, Zhejiang Province Applicant after: Hangzhou Huawei Medical Technology Co., Ltd. Address before: O 03-04 Changhong technology building 18 unit 9 floor No. 518000 Guangdong city of Shenzhen province Nanshan District Guangdong science and Technology Street twelve South Road Applicant before: Huawei (Shenzhen) Medical Devices Co., Ltd. |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180413 |